Attovia Therapeutics

General Information
Business:	(Incorporated in Delaware) We are a Phase 1 clinical biopharmaceutical company developing next-generation biologics for immune-mediated diseases. We use our ATTOBODY platform, a biparatropic nanobody-based technology licensed from Alamar Biosciences. We have no products on the market. And we have no revenue from product sales. Our lead drug candidate, ATTO-1310, is an ATTOBODY-based therapeutic that targets IL-31 (interleukin-31). We have completed dosing in a Phase 1 clinical trial in healthy volunteers and patients with chronic pruritus and atopic dermatitis in the first quarter of 2026. Our second candidate, ATTO-2306, is an ATTOBODY-based bispecific targeting IL-13 and IL-31 for atopic dermatitis and related skin conditions. It’s in IND-enabling studies with a Phase 1 trial planned for the first half of 2027. (IND stands for investigational new drug.) Our third candidate, ATTO-1091, is a trispecific ATTOBODY-based Fc fusion protein designed to block TL1A, IL-23, and integrin a4ß7 simultaneously for inflammatory bowel disease; this drug candidate is also in IND-enabling studies. Note: Collaboration revenue is for the 12 months that ended on March 31, 2026. (Note: Attovia Therapeutics filed its S-1 for its IPO on July 14, 2026, without disclosing the terms. Estimated proceeds are $100, a placeholder figure.)
Industry:	Pharmaceuticals
Employees:	44
Founded:	2022
Contact Information
Address	1091 Industrial Road, Suite 310 San Carlos, California 94070
Phone Number	(510) 399-5001
Web Address	https://www.attovia.com/
View Prospectus:	Attovia Therapeutics
Financial Information
Market Cap
Revenues	$1.35 mil (last 12 months)
Net Income	$-64.13 mil (last 12 months)
IPO Profile
Symbol	ATTO
Exchange	NASDAQ
Shares (millions):	0.0
Price range	$0.00 - $0.00
Est. $ Volume	$100.0 mil
Manager / Joint Managers	Morgan Stanley/Leerink Partners/Citigroup/RBC Capital Markets/LifeSci Capital
CO-Managers
Expected To Trade:
Status:	TBA
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

Attovia Therapeutics

(Incorporated in Delaware)

Our lead drug candidate, ATTO-1310, is an ATTOBODY-based therapeutic that targets IL-31 (interleukin-31). We have completed dosing in a Phase 1 clinical trial in healthy volunteers and patients with chronic pruritus and atopic dermatitis in the first quarter of 2026.

Our second candidate, ATTO-2306, is an ATTOBODY-based bispecific targeting IL-13 and IL-31 for atopic dermatitis and related skin conditions. It’s in IND-enabling studies with a Phase 1 trial planned for the first half of 2027. (IND stands for investigational new drug.)

Our third candidate, ATTO-1091, is a trispecific ATTOBODY-based Fc fusion protein designed to block TL1A, IL-23, and integrin a4ß7 simultaneously for inflammatory bowel disease; this drug candidate is also in IND-enabling studies.

Note: Collaboration revenue is for the 12 months that ended on March 31, 2026.

(Note: Attovia Therapeutics filed its S-1 for its IPO on July 14, 2026, without disclosing the terms. Estimated proceeds are $100, a placeholder figure.)